OSPN OneSpan delivers 20 percent Q4 2025 EPS beat shares rise modestly on upbeat investor reception PCSA Processa Pharmaceuticals posts worsethanexpected Q4 2025 EPS results that miss estimates by 68 percent as shares edge 033 percent lower JPMorgan Chase JPM Equity Strategy Team Reiterates Bullish Buy the Dips Call Amid Expected Broadening Market Leadership